On this site you will find clinical studies with cannabis or single
cannabinoids in different diseases and case reports on the use of cannabis by
You may search for diseases (indications), authors, medication,
study design (controlled study, open trial, case report etc.) and other criteria.
|Title||Safety and efficacy of dronabinol in the treatment of agitation in patients with Alzheimer’s disease with ANOREXIA: A retrospective chart review|
|Author(s)||Patel S, Shua-Haim JR, Pass M|
|Journal, Volume, Issue||Abstract, International Psychogeriatric Association, Eleventh International Congress, 2003|
|Major outcome(s)||Weight gain in all, reduction of agitation in 65%.|
|Indication||Appetite loss/weight loss;Alzheimer's disease||Abstract
Objective: to investigate the safety and efficacy of dronabinol in Alzheimer’s disease (AD) patients with agitation.
Design: retrospective review.
Materials and Methods: AD patients with ANOREXIA, where according to family members or caregivers (staff nurses) agitation was not satisfactorily controlled, were prescribed dronabinol. All met the DSM-IV & NINCDS-ADRDA criteria for possible AD. There were no exclusion criteria. Study subjects resided in a dementia unit in assistant living facility and in a nursing home. Dronabinol, 5 mg/day in 2 divided doses was given initially & titrated up to a maximum of 10 mg/day. Cognition and function evaluated at the start and end of the study period. MMSE and ADL scales used for assessment. Concomitant medications were recorded. After 1 month of treatment, caregivers were asked to complete a questionnaire regarding their impression on treatment efficacy.
Results: 48 patients were treated with dronabinol. Average age was 77. Average MMSE was 16. All patients were treated with atypical neuroleptics. All were treated with multiple (greater than 3) medications to control behavior. All patients had diagnoses of ANOREXIA prior to initiation of dronabinol therapy. Weight gain was reported in all patients. Agitation significantly improved in 31 (65%). In 14 (37%) there was improvement in MMSE score (average increase by 1.6 points (range +1 to +3). Functional improvement was reported in 33 (69%). 17 (35%) patients had no significant beneficial effect with regard to agitation, and their medication was discontinued within 2 weeks of initiation of treatment. No patient experienced any significant adverse event (falls, syncope, seizures or exacerbation of agitation/depression).
Conclusion: Dronabinol treatment for agitation in AD patients with ANOREXIA was effective in 31 out of 48 of patients who were refractory to other medications. No adverse events were reported.
|Participants||48 Alzheimer patients|
|Type of publication||Meeting abstract|
|Address of author(s)||Meridian Institute for Aging, Manchester Township, NJ, USA|